CCR5 Ligands in HIV Vaccines

clinical phenotypes, defined racial backgrounds, and quantified risk. Mol Med
1997;3:23-36.AGD20. Quillent C, Oberlin E, Braun J, Rousset D, Gonzalez-Canali
G, Metais P, Montagnier L, Virelizier JL, Arenzana-Seisdedos F, Beretta A. HIV-1 -resistance phenotype conferred by combination of two separate inherited mutations
of CCR5 gene. Lancet 1998 351:14-18.
36. Schols D, Proost P, Struyf S, Wuyts A, De Meester I, Scharpe S, Van Damme J, De
Clercq E. CD26-processed RANTES(3-68), but not intact RANTES, has potent antiHIV-1 activity. Antiviral Res. 1998 39:175-187.
37. Oravecz T, Pall M, Roderiquez G, Gorrell MD, Ditto M, Nguyen NY, Boykins R,
Unsworth E, Norcross MA: Regulation of the receptor specificity and function of
the chemokine RANTES (regulated on activation, normal T cell expressed and
secreted) by dipeptidyl peptidase IV (CD26)-mediated cleavage. J Exp Med
186:1865-1872, 1997
38. Struyf S, De Meester I, Scharpe S, Lenaerts JP, Menten P, Wang JM, Proost P, Van
Damme J: Natural truncation of RANTES abolishes signaling through the CC
chemokine receptors CCR1 and CCR3, impairs its chemotactic potency and
generates a CC chemokine inhibitor. Eur J Immunol 28:1262-1271, 1998
39. Proost P, De Meester I, Schols D, Struyf S, Lambeir AM, Wuyts A, Opdenakker G,
De Clercq E, Scharpe S, Van Damme J: Amino-terminal truncation of chemokines
by CD26/dipeptidyl-peptidase IV. Conversion of RANTES into a potent inhibitor of
monocyte chemotaxis and HIV-1-infection. J Biol Chem 273:7222-7227, 1998.
40. Nibbs RJ, Yang J, Landau NR, Mao JH, Graham GJ: LD78beta, a non-allelic
variant of human MIP-1 alpha (LD78alpha), has enhanced receptor interactions and
potent HIV suppressive activity. J Biol Chem, 274:17478-17483, 1999
41. Menten P, Struyf S, Schutyser E, Wuyts A, De Clercq E, Schols D, Proost P, Van
Damme J. The LD78beta isoform of MIP-lalpha is the most potent CCR5 agonist
and HIV-1-inhibiting chemokine. J Clin Invest. 1999 104:R1-R5.
42. Xin X, Shioda T, Kato A, Liu H, Sakai Y, Nagai Y. Enhanced anti-HIV-1 activity
of CC-chemokine LD78beta, a non-allelic variant of MIP-lalpha/LD78alpha.
FEBS Lett. 1999 457:219-222.
43. Aquaro S, Menten P, Struyf S, Proost P, Van Damme J, De Clercq E, Schols D. The
ld78beta isoform of mip-lalpha is the most potent cc-chemokine in inhibiting ccr5 -dependent human immunodeficiency virus type 1 replication in human
macrophages. J Virol. 2001 75:4402-4406.
44A NakaoMyomiyam -Shi-ada-K--trueM-s--huma-gene-g-a-g for
cytokine LD78 and their expression. Mol Cell Biol. 1990 Jul; 10(7):3646-58
45. Garzino-Demo A, Gallo RC, Arya SK: Human immunodeficiency virus type 2
(HIV-2): packaging sigual and associated negative regulatory element. Hum Gene
Ther 6:177-184, 1995.
46. Doherty PJ, Huesca-Contreras M, Dosch HM, Pan 5: Rapid amplification of
complementary DNA from small amounts of unfractionated RNA. Anal Biochem
177:7-10, 1989.

13